KOL Insight

Follicular Lymphoma KOL Interview – Germany

This interview with a German KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Future trends and unmet needs are also discussed. Key drug classes highlighted include anti-CD20 antibodies (Rituxan and Gazyva), immunomodulators (Revlimid), autologous CAR-T therapies (Yescarta and Kymriah), CD20 x CD3 bispecifics (Lunsumio), BTK inhibitors (Imbruvica and Brukinsa), EZH2 inhibitors (Tazverik), PI3 kinase inhibitors (Copiktra, Zydelig, Aliqopa, and zandelisib), and anti-CD19 antibodies (Monjuvi).

Macitenan for Pulmonary Arterial Hypertension

Macitentan is a novel dual endothelin receptor antagonist (ERA)

showing sustained receptor occupancy

Datamonitor Healthcare Type 2 Diabetes KOL Interview – UK

In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.